Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 · New England Journal of Medicine · 4,204 citations
https://doi.org/10.1056/nejmoa1809615
S
Sylvia Adams
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
347
Papers
31.1K
Citations
72
h-index
157
i10-index
Sylvia Adams is an academic researcher from NYU Langone Health. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & Advanced Breast Cancer Therapies. The author has an h-index of 72, co-authored 295 publications.
ORCID: 0000-0003-4737-1952Papers by this author
worksAtezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · The Lancet Oncology · 1,172 citations
https://doi.org/10.1016/s1470-2045(19)30689-8
NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis
2017 · Nature · 776 citations
https://doi.org/10.1038/nature24637
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
2018 · Annals of Oncology · 756 citations
https://doi.org/10.1093/annonc/mdy517
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
2016 · JAMA Oncology · 627 citations
https://doi.org/10.1001/jamaoncol.2016.1061
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
2018 · Annals of Oncology · 608 citations
https://doi.org/10.1093/annonc/mdy518
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat